Mitoxantrone Hydrochloride Liposome Combined With Capecitabine in Patients With HER-2 Negative Advanced Breast Cancer

Breast Cancer Clinical Trial

Official title:

Clinical Study of Mitoxantrone Hydrochloride Liposome Injection Combined With Capecitabine in Patients With HER-2 Negative Advanced Breast Cancer

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT06156761
• Other study ID #: CSPC-DED-BC-K01
• Status: Not yet recruiting
• Phase: N/A
• Start date: November 28, 2023
• Est. completion date: April 2025

Study information

• Verified date: December 2023
• Source: Cancer Institute and Hospital, Chinese Academy of Medical Sciences
• Contact: Binghe Xu, PHD
• Phone: 86-10-87788495
• Email: xubinghe[@]medmail.com.cn
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

To evaluate the dose-limiting toxicity of mitoxantrone hydrochloride liposome combined with capecitabine in patients with HER-2 negative advanced breast cancer who have received at least first-line treatment, explore the maximum tolerated dose (MTD) of mitoxantrone hydrochloride liposome, and determine the recommended phase II dose (RP2D).

Description:

This is a single-center, open-label, phase I dose-increasing study following the "3+3" principle, which planned to enroll a maximum of 48 clinically confirmed patients with advanced HER-2 negative breast cancer who have received at least first-line treatment, to explore the MTD of mitoxantrone hydrochloride liposome.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 24
• Est. completion date: April 2025
• Est. primary completion date: April 2024
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

1. Patients fully understand and voluntarily participate in this study and sign the informed consent form.

2. Age =18 and =70 years, Female.

3. Histopathologically confirmed HER-2 negative breast cancer (Immunohistochemical HER-2 0/1+ or immunohistochemical HER-2 2+ that had to be confirmed as negative by in situ hybridization).

4. Hormone receptor (HR) negative, HR positive but ineligible for endocrine therapy, or HR positive but resistant to endocrine therapy.

5. Recurrent or metastatic breast cancer that have failed at least one line of chemotherapy or ADC. And previous endocrine therapy was not counted.

6. Previous treatment with taxanes and/or anthracyclines.

7. Relapse occurred no less than 12 months after the last dose of an anthracycline-containing adjuvant chemotherapy regimen.

8. Have at least one measurable disease according to RECIST 1.1.

9. ECOG (Eastern Cooperative Oncology Group) performance status of 0-1.

10. LVEF=50%.

11. Good bone marrow function (no blood transfusion or growth factor support within 2 weeks before the first dose of trial medication): WBC=3.0×10^9/L, ANC =1.5×10^9/L, PLT =75×10^9/L, Hb=90g/L.

12. Pregnancy tests were negative, and patients of childbearing age committed to use effective contraception or abstinence from sex from the start of the study until 6 months after the last study dose.

13. Expected survival time greater than 3 months.

14. Good compliance and willingness to cooperate with follow-up visits.

Exclusion Criteria:

1. Patients have one of the following conditions in the previous anti-tumor treatments:

1. Previous treatment with mitoxantrone or mitoxantrone liposome:

2. Previous treatment with doxorubicin or epirubicin (total cumulative dose of doxorubicin>350mg/m^2, total cumulative dose of epirubicin>700mg/m^2);

3. Has received anti-tumor treatment (including chemotherapy, targeted therapy, hormone therapy, taking traditional Chinese medicine with anti-tumor activity, etc.) or participated in other clinical trials and received clinical trial drugs within 4 weeks before the first use of the study drugs.

2. Abnormal heart function, including:

1. Long QTc syndrome or QTc interval > 480ms;

2. Complete left bundle branch block, degree II or III atrioventricular block;

3. Severe, uncontrolled arrhythmias requiring medical treatment;

4. New York Heart Association grade = II;

5. A history of myocardial infarction, unstable angina, severe unstable ventricular arrhythmia or any other arrhythmia requiring treatment, a history of clinically significant pericardial disease, or ECG evidence of acute ischemia or active conduction system abnormalities within 6 months before recruitment.

3. Previous or current concurrent malignancy other than breast cancer.

4. Have any serious and/or uncontrolled medical conditions that in the judgment of the investigator may affect the patient's participation in the study (including advanced infection, uncontrolled diabetes or hypertension, severe liver disease, etc.).

5. Have uncontrolled brain metastases.

6. Chronic hepatitis B (HBsAg or HBcAb positive and HBV DNA=1000IU/mL), chronic hepatitis C (HCV antibody positive and HCV RNA higher than the lower limit of the detection value of the research center), or HIV antibody positive.

7. Participants who are known to be allergic to the active or other components of the study treatment.

8. Pregnant or lactating women.

9. A history of severe neurological or psychiatric illness.

10. Participants who were judged by the investigator to be unsuitable for this study.

Related Conditions & MeSH terms

• Breast Cancer
• Breast Neoplasms

Intervention

Drug:
• Mitoxantrone hydrochloride liposome
Drug: Mitoxantrone hydrochloride liposome (16 mg/m^2, 18 mg/m^2, 20 mg/m^2 and 22 mg/m^2) will be administered by intravenous infusion on day 1 in a 3-week treatment cycle.
• Capecitabine
Capecitabine (1000 mg/m^2) will be administered orally in a 3-week treatment cycle, twice a day from day 1 to day 14 of each cycle.
• Mitoxantrone hydrochloride liposome
Mitoxantrone hydrochloride liposome (16 mg/m^2, 18 mg/m^2, 20 mg/m^2 and 22 mg/m^2) will be administered by intravenous infusion on day 1 in a 4-week treatment cycle.
• Capecitabine
Capecitabine (825 mg/m^2) will be administered orally in a 4-week treatment cycle, twice a day from day 1 to day 21 of each cycle.

Locations

Country	Name	City	State
China	Cancer Hospital Chinese Academy of Medical Sciences	Beijing	Beijing

Sponsors (2)

Lead Sponsor	Collaborator
Cancer Institute and Hospital, Chinese Academy of Medical Sciences	CSPC Ouyi Pharmaceutical Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	MTD of mitoxantrone hydrochloride liposome	To evaluate the tolerability of mitoxantrone hydrochloride liposome combination regime	At the end of Cycle 1 (each cycle is 21 days or 28 days)
Secondary	Safety: Hematologic and non-hematologic toxicities (NCI CTCAE v5.0)	To identify the incidence of AE and SAE in clinical trial	From the initiation of the first dose to 21 or 28 days after the last dose
Secondary	Objective response rate (ORR)	To evaluate the efficacy of anti-tumor	21 or 28 days after the last dose
Secondary	Disease control rate (DCR)	To evaluate the efficacy of anti-tumor	21 or 28 days after the last dose
Secondary	Progression-free survival (PFS)	To evaluate the efficacy of anti-tumor	one year after the last dose